Source - RNS
RNS Number : 8817L
e-Therapeutics plc
06 October 2016

e-Therapeutics plc

('e-Therapeutics' or 'the Company')


Directors' Dealings and Issue of Equity


Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,204 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at an average price of 11.327 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones Non-Executive Director fees net of tax paid during the period from 1 May 2016 to 30 September 2016.


Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 12 October 2016. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.


Following Admission, Professor Jones will be interested in a total of 70,580 ordinary shares of 0.1p in the Company, representing approximately 0.03% of the Company's issued share capital.


Following Admission the total number of ordinary shares in the Company with voting rights in issue will be 268,389,125. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.


The Company also announces today that on 5 October 2016 Professor Jones entered into a binding contractual arrangement with the Company under which he agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-Therapeutics' ordinary shares.


The new shares will be issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid will be the average of the closing mid-market price for the five business days prior to the date of issue. The terms pursuant to which Professor Jones will purchase the shares are fixed and he has irrevocably committed to such terms.




Details of the person discharging managerial responsibilities/person closely associated



Trevor Jones


Reason for the notification





Initial notification /Amendment

Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



e-Therapeutics plc


Legal Entity Identifier



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

Ordinary shares of 0.1 pence each






Nature of the transaction

Purchase of new shares





Price(s) and volume(s)



11.327 pence



Aggregated information

- Aggregated volume

- Price

- Aggregated total



11.327 pence



Date of the transaction

5 October 2016


Place of the transaction

London Stock Exchange










e-Therapeutics plc

Iain Ross, Chairman

Steve Medlicott, Finance Director


Tel: +44 (0) 1993 883 125 


Numis Securities Limited

Michael Meade / Freddie Barnfield (Corporate Finance)

James Black (Corporate Broking)


Tel: +44 (0) 207 260 1000


Instinctif Partners

Melanie Toyne Sewell / Jayne Crook / Emma Barlow

Tel: +44 (0) 207 457 2020

Email: [email protected]


About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 


e-Therapeutics has a variety of preclinical stage assets, including ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  


The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit





This information is provided by RNS
The company news service from the London Stock Exchange